Prevalence, risk factors and clinical characteristics of lipohypertrophy in insulin-treated patients with diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20190707003

Enrollment

Unknown

Registered

2019-07-07

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

A total of 400 insulin&#45

treated patients were recruited from June 2018 to March 2019 at Theptarin Hospital.

Diagnostic

Insulin&#45

treated DM patients

Eligibility

Sex/Gender

All

Age

15 Years to 100 Years

Inclusion criteria

Inclusion criteria: -Insulin treated DM patients (both T1DM and T2DM) who are regularly F/U at Theptarin Hospital at least 3 times per year -Continuation of insulin treatment at least 6 months

Exclusion criteria

Exclusion criteria: - Non-insulin treated DM patients - Use of insulin less than 6 months - Irregular or lost to F/U patients

Design outcomes

Primary

Measure	Time frame
The presence of lipohypertrophy 9 months Percentage	—

Secondary

Measure	Time frame
Severity of Lipohypertrophy, Patients' awareness of Lipohypertrophy 9 months Grading of Lipohypertrophy based on observation and palpation technique, Awareness Questionnaire	—

Countries

Thailand

Contacts

Public ContactHussamon Prasatkaew

Theptarin Hospital

hussa7494@gmail.com+66023487000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Prevalence&#44; risk factors and clinical characteristics of lipohypertrophy in insulin&#45;treated patients with diabetes